Friday, 13 Sep 2019

You are here

VEGF121-Fibrin as a Potential Therapy for Skin Ulcers in Systemic Sclerosis

The etiology of systemic sclerosis (SSc) remains unclear, but appears to involve complex pathogenic interactions between the immune system, the vasculature and fibrotic processes. Better understanding of such interactions could lead to discovery of new therapeutic approaches, and requires appropriate animal models.

The University of California at Davis chicken lines 200 and 206 are one such animal model displaying all hallmarks of SSc. While SSc is characterized by uncontrolled overexpression of vascular endothelial growth factor (VEGF), this results in chaotic vessels and the cutaneous ulcerations. 

In this animal model study, it was hypothesised that local administration of VEGF121-fibrin and consequent cell demanded release of VEGF from the fibrin matrix would overcome the uncontrolled VEGF expression found in SSc, and induce sufficient angiogenesis to heal and prevent ischemic ulcers.

Ninety-one early and late ischemic comb and neck skin lesions of UCD-206 chickens were treated locally with VEGF121-fibrin, fibrin alone, or left untreated. After 1 week of treatment the clinical outcome was assessed. Angiogenesis was studied by immunofluorescence staining of vascular markers quantitatively analyzed using TissueQuest.

Overall, 79.3% of the VEGF121-fibrin treated lesions showed clear clinical improvement, whereas 71.0% of fibrin treated controls and 93.1% of untreated lesions had deteriorated.

The study results suggest that VEGF121 from fibrin matrix induces controlled angiogenesis by differential regulation of VEGFR-1 and VEGFR-2 expression, shifting the balance towards the pro-angiogenic VEGFR-2. The study shows the potential of covalently conjugated VEGF-fibrin matrices for the treatment of ischemic lesions such as fingertip ulcers.  The long-term effects and potential side effects of VEGF121 will require further clinical study.

Dr. Olga Petryna
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Riociguat Fails in Systemic Sclerosis-Associated Digital Ulcers

Riociguat is an oral, selective soluble guanylate cyclase stimulator that has been studied in patients with digital ulcers (DU) due to systemic sclerosis (SSc) but study results show that short term (16 weeks) riociquat therapy does not sufficiently reduce the DU burden in SSc patients.

Nintedanib FDA Approved for Scleroderma Lung Disease

Last Friday, the US Food and Drug Administration approved Ofev (nintedanib) to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. ILD as a complication of SSc may lead to progressive loss of lung function and may be associated with a significant mortality risk. Prior to the approval of Olev, there were no FDA approved drugs for SSc-ILD.

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS).